The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension

Buda, Valentina; Andor, Minodora; Cristescu, Carmen; Voicu, Mirela; Cochera, F.; Tuduce, P.; Petrescu, Lucian; Tomescu, Mirela Cleopatra

doi:10.1007/s11845-017-1580-5

Cited by 11 publications

(13 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Only ACEIs increased the vascular response of the forearm to reactive hyperemia by increasing NO production in these patients with essential hypertension. Buda et al [60] demonstrated in a cross-sectional study that treatment with candesartan was associated with lower plasma levels of pentraxin-3 (PTX3) and CRP compared to other classes of antihypertensive drugs (β-blockers, calcium channel blocker, and diuretics) in 365 patients with essential hypertension. On the other hand, Vidal et al [61] showed in a prospective population-based study conducted in Switzerland that the use of ARB was not associated with reduced levels of inflammatory markers when compared with non-users (users of other classes of antihypertensive drugs).…”

Section: Antihypertensive Drugs Endothelial Dysfunction and Inflmentioning

confidence: 99%

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation

Silva

Figueiredo

Rios

2019

IJMS

124

View full text Add to dashboard Cite

Hypertension is characterized by structural and functional changes in blood vessels that travel with increased arterial stiffness, vascular inflammation, and endothelial dysfunction. Some antihypertensive drugs have been shown to improve endothelial function and reduce levels of inflammatory markers regardless of the effect of blood pressure lowering. Third-generation β-blockers, such as nebivolol and carvedilol, because they have additional properties, have been shown to improve endothelial function in patients with hypertension. Calcium channel antagonists, because they have antioxidant effects, may improve endothelial function and vascular inflammation.The Angiotensin Receptor Blocker (ARBs) are able to improve endothelial dysfunction and vascular inflammation in patients with hypertension and other cardiovascular diseases. Angiotensin converting enzyme (ACE) inhibitors have shown beneficial effects on endothelial function in patients with hypertension and other cardiovascular diseases, however there are few studies evaluating the effect of treatment with this class on the reduction of C-reactive protein (CRP) levels. Further studies are needed to assess whether treatment of endothelial dysfunction and vascular inflammation may improve the prognosis of patients with essential hypertension.

show abstract

Section: Antihypertensive Drugs Endothelial Dysfunction and Inflmentioning

confidence: 99%

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation

Silva

Figueiredo

Rios

2019

IJMS

124

View full text Add to dashboard Cite

show abstract

“…Even if in the case of pharmaceuticals, the term "stability" is usually correlated with the loss of the active pharmaceutical ingredient from formulation, and "solid-state stability" can also designate the response of an API or a pharmaceutical formulation to thermal stress. However, in both cases, the decomposition of the API due to chemical processes or even physical transitions (phase transitions such as polymorphism and crystallization) in the presence of excipients dictates Acting in a dose-dependent manner, candesartan can be used in several pathologies such as essential arterial hypertension [5], ventricular hypertrophy [6], heart failure [7], diabetic nephropathy, [8] retinopathy [9], myocardial infarction [10], endothelial dysfunction [6,11], prehypertension [12], the prevention of atrial fibrillation [13], migraine prophylaxis [14], and stroke [15]. Recently, it has been shown to ameliorate brain inflammation associated with Alzheimer's disease [16] and to induce neuroprotective effects in patients suffering from Parkinson's disease [17].…”

Section: Introductionmentioning

confidence: 99%

Solid State Stability and Kinetics of Degradation for Candesartan—Pure Compound and Pharmaceutical Formulation

et al. 2020

View full text Add to dashboard Cite

The aim of this work was to assess the impact of an excipient in a pharmaceutical formulation containing candesartan cilexetil over the decomposition of the active pharmaceutical ingredient and to comparatively investigate the kinetics of degradation during thermolysis in an oxidative atmosphere under controlled thermal stress. To achieve this, the samples were chosen as follows: pure candesartan cilexetil and a commercial tablet of 32 mg strength. As a first investigational tool, Universal attenuated total reflection Fourier transform infrared (UATR-FTIR) spectroscopy was chosen in order to confirm the purity and identity of the samples, as well as to check if any interactions took place in the tablet between candesartan cilexetil and excipients under ambient conditions. Later on, samples were investigated by thermal analysis, and the elucidation of the decomposition mechanism was achieved solely after performing an in-depth kinetic study, namely the use of the modified non-parametric kinetics (NPK) method, since other kinetic methods (American Society for Testing and Materials—ASTM E698, Friedman and Flynn–Wall–Ozawa) led to inadvertencies. The NPK method suggested that candesartan cilexetil and the tablet were degraded by the contribution of two steps, the main being represented by chemical degradation and the secondary being a physical transformation. The excipients chosen in the formulation seemed to have a stabilizing effect on the decomposition of the candesartan cilexetil that was incorporated into the tablet, relative to pure active pharmaceutical ingredient (API), since the apparent activation energy for the decomposition of the tablet was 192.5 kJ/mol, in comparison to 154.5 kJ/mol for the pure API.

show abstract

“…Plasma PTX3 concentration is reportedly normalized by cardiovascular drugs, including antihypertensive 23–27 , antilipemic 28 , and antithrombotic 29 agents. Although the drug screening test detected the antithrombotic drug warfarin in two cases (case Nos.…”

Section: Resultsmentioning

confidence: 99%

Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome

Tojo

Shintani-Ishida

Tsuboi

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Pentraxin 3 (PTX3) is an acute-phase protein that belongs to the pentraxin superfamily. Recently, many clinical studies have demonstrated that plasma PTX3 concentrations rapidly increase in patients with the acute coronary syndrome (ACS). The aim of this study was to evaluate the forensic utility of postmortem plasma PTX3 as a marker of fatal ACS. We compared the plasma PTX3 concentration in cadavers with suspected fatal ACS to that exhibited in control cases (e.g., asphyxia and immediate death due to a fatal injury). The ACS groups included a coronary stenosis group, which exhibited apparent coronary stenosis, but an absence of coronary thrombi, a coronary thrombi group with thrombi found in the coronary artery, and a group of myocardial rupture following an acute myocardial infarction. The plasma PTX3 concentration was significantly higher in the coronary thrombi group than the control group and other ACS groups. The postmortem plasma PTX3 concentration was higher than the clinical reference values, which appeared to be caused by a postmortem release from circulating neutrophils. In conclusion, although the clinical reference value cannot be applied to postmortem samples, the postmortem plasma PTX3 concentration may be a useful marker of death occurring immediately after the onset of fatal ACS.

show abstract

The effect of candesartan on pentraxin-3 plasma levels as marker of endothelial dysfunction in patients with essential arterial hypertension

Cited by 11 publications

References 31 publications

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation

Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation

Solid State Stability and Kinetics of Degradation for Candesartan—Pure Compound and Pharmaceutical Formulation

Postmortem plasma pentraxin 3 is a useful marker of fatal acute coronary syndrome

Contact Info

Product

Resources

About